PRTG — Portage Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $4.53m
- -$1.20m
- 13
- 54
- 13
- 16
Annual cashflow statement for Portage Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.59 | -7.25 | -17.2 | -19.2 | -105 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.02 | 3.65 | 11.2 | 8.47 | 110 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.715 | -0.114 | -0.744 | -0.461 | -0.01 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.858 | -3.71 | -4.28 | -6.76 | -12.1 |
| Capital Expenditures | — | — | — | — | -0.003 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.446 | 0 | -0.86 | 0 | -0.614 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.446 | 0 | -0.86 | 0 | -0.617 |
| Financing Cash Flow Items | — | 1 | -1.25 | -1.85 | -1.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.05 | 0.7 | 4.76 | 27.3 | -0.117 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.35 | -3.01 | -0.382 | 20.6 | -12.8 |